Nonalcoholic steatohepatitis is liver inflammation and damage caused by a buildup of fat in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease. It leads to cirrhosis and increasing risk of liver failure and hepatocellular carcinoma in some cases. The global non-alcoholic steatohepatitis market will reach 9727.96 million USD by 2023 from 4124.74 million USD in 2018 with a CAGR of 13.04% during the period.
Growth by Region
Asia Pacific will grow with high CAGR owing to growth in diagnostic techniques, rise in prevalence NASH and developing healthcare infrastructure. North America held largest share in the market due to prevalence of NASH and presence of pipeline drugs.
Drivers vs Constraints
Increasing cases of diabetics and obesity is the major factor driving the growth of the market. Growth in demand for NASH therapeutics and rise in prevalence of NASH are the factors driving the market. However, lack of diagnostic technologies for NASH is hampering the market growth.
Industry Trends and Updates
AstraZeneca licensed IONIS-AZ6-2.5-LRx, NASH drug from Ionis Pharmaceuticals, Inc. for USD 30 million.
Allergan acquired Tobira Therapeutics Inc. and Akarna Therapeutics Ltd., which provides Allergan a readymade pipeline for the potentially lucrative NASH market.
Global Non-alcoholic Steatohepatitis Market – by Drug Type, Region - Market Size, Demand Forecasts, Company Profiles, Industry Trends and Updates (2018 - 2025)
1. Research Methodology
2. Executive Summary
3. Market Overview
3.1. Definition
3.2. Industry Value Chain Analysis
3.3. Porter's 5 Forces
3.4. Regulations
4. Market Dynamics
4.1. Introduction
4.2. Drivers
4.3. Constraints
4.4. Trends
5. Global Non-alcoholic Steatohepatitis Market Segmentation, Forecasts and Trends - by Drug
5.1. Obeticholic Acid
5.2. Aramchol
5.3. Saroglitazar
5.4. Elafibranor
5.5. Others
6. Global Non-alcoholic Steatohepatitis Market Segmentation, Forecasts and Trends - by Region
6.1. North America
6.1.1. U.S.
6.1.2. Canada
6.1.3. Mexico
6.2. Europe
6.2.1. UK
6.2.2. France
6.2.3. Germany
6.2.4. Italy
6.2.5. Others
6.3. Asia Pacific
6.3.1. India
6.3.2. China
6.3.3. Japan
6.3.4. Australia
6.3.5. Others
6.4. South America
6.4.1. Brazil
6.4.2. Argentina
6.4.3. Others
6.5. Middle East and Africa
6.5.1. South Africa
6.5.2. UAE
6.5.3. Saudi Arabia
6.5.4. Egypt
6.5.5. Others
7. Competitive Intelligence
7.1. Company Market Share Analysis
7.2. Industry M&As, Consolidations
8. Company Profiles
8.1. AstraZeneca
8.2. Intercept Pharmaceutical
8.3. Galmed Pharmaceutical
8.4. Genfit
8.5. Allergan
8.6. Gilead Science
8.7. Zydus Cadila
8.8. Immuron
8.9. Conatus Pharmaceutical
8.10. Novo Nordisk
8.11. Enzo Biochem
8.12. Raptor Pharmaceutical
8.13. Tobira Therapeutics
8.14. Prometheus Laboratories
8.15. Siemens Healthcare
8.16. Others
9. Investment Opportunities